Elevated Treasury yields near 19-year highs and AI-related valuation scrutiny have tempered the fall 2026 IPO window, prompting several postponements including Oura and others in Q3, yet the pipeline remains active with multiple corporate and SPAC offerings pricing in early October. Through mid-September, 109 deals raised $146.5 billion, pacing toward a strong year, while recent S-1 filings and pricings signal continued issuer demand. Key catalysts ahead include potential Anthropic and other AI-adjacent listings by year-end alongside routine biopharma and infrastructure debuts. Traders monitoring Fed policy, 10-year yields, and aftermarket performance view the market as receptive enough for additional transactions before 2027, though selectivity favors larger, fundamentally sound issuers over broad participation.